The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CABA | -44.32% | -80.81% | -28.09% | -75% |
| S&P | +12.65% | +91.73% | +13.89% | +123% |
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.47M | -9.9% |
| Market Cap | $136.71M | -62.1% |
| Market Cap / Employee | $0.85M | 0.0% |
| Employees | 161 | 56.3% |
| Net Income | -$45.13M | -63.5% |
| EBITDA | -$45.44M | -52.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $145.61M | -18.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.48M | 0.0% |
| Short Term Debt | $20.41M | 175.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -65.30% | -20.5% |
| Return On Invested Capital | -44.16% | -12.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$30.59M | -41.9% |
| Operating Free Cash Flow | -$30.43M | -46.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.14 | 0.64 | 0.46 | 0.63 | -61.02% |
| Price to Tangible Book Value | 1.14 | 0.64 | 0.46 | 0.63 | -61.02% |
| Enterprise Value to EBITDA | -2.01 | 1.03 | 0.89 | 1.67 | -128.59% |
| Return on Equity | -62.2% | -59.6% | -73.9% | -76.3% | 58.51% |
| Total Debt | $15.22M | $15.60M | $28.79M | $24.89M | 236.39% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
